Keyphrases
AXL Inhibition
19%
Cancer Patients
14%
Cancer Types
13%
Chemotherapy Resistance
12%
Chemotherapy Response
12%
Complication Rate
19%
COVID-19 Pandemic Impact
19%
Endometrial Cancer
48%
Excision
19%
Gynecologic Malignancies
15%
Gynecologic Oncology
59%
Gynecologic Surgery
13%
Gynecological Cancer
27%
High-grade Serous Ovarian Cancer (HGSOC)
39%
Homologous Recombination Deficiency
12%
Hysterectomy
13%
Immunohistochemistry
14%
Molecular Targeted Therapy
14%
Oncology Care
13%
Oncology Patients
23%
Organoids
17%
Ovarian Cancer
40%
Ovarian Cancer Patients
41%
Ovarian Metastasis
22%
Ovarian Organoid
13%
Overall Survival
26%
Paclitaxel
12%
Palliative Care
19%
PARP Inhibitor (PARPi)
11%
Patient-derived
17%
Patient-derived Organoids
19%
Pembrolizumab
11%
Perioperative Antibiotics
11%
Platinum-based Chemotherapy
18%
Platinum-free Interval
13%
Predictive Biomarker
14%
Primary Tumor
13%
Prophylactic Antibiotics
11%
RAD51 Foci
14%
Recurrent Endometrial Cancer
21%
Society of Gynecologic Oncology
13%
Survival Outcomes
15%
Treatment Options
14%
Tumor
24%
Tumor Burden
12%
Tumor Cells
25%
Tumor Microenvironment
21%
Vertical Incision
12%
Vulvar
13%
Wound Complications
36%
Medicine and Dentistry
Acute Chest Syndrome
9%
Adipose Tissue
9%
Antibiotics
12%
Biological Marker
14%
Cancer
19%
Cell Line
17%
Chlamydia Trachomatis
9%
COVID-19
19%
Cytoreductive Surgery
9%
Direct Oral Anticoagulant
9%
Diseases
16%
DNA Damage
10%
DNA Repair
13%
Drive
10%
End of Life Care
9%
Female Genital Tract Cancer
22%
Frailty
11%
Frailty Index
19%
Gestagen
9%
Gynecological Oncology
59%
Gynecological Surgery
13%
Homologous Recombination
15%
Hysterectomy
13%
Immunofluorescence Test
9%
Immunohistochemistry
13%
Immunotherapy
9%
In Vitro
10%
Incision
12%
Malignant Neoplasm
22%
Mesothelial Cell
10%
Metastatic Carcinoma
33%
Neoplasm
45%
Organoid
39%
Ovarian Cancer
100%
Overall Survival
18%
Paclitaxel
11%
Patient Referral
13%
Pembrolizumab
11%
Poly ADP Ribose Polymerase
11%
Primary Health Care
9%
Primary Tumor
10%
Randomized Controlled Trial
11%
Recurrent Disease
15%
Sickle Cell
9%
Subcutaneous Fat
9%
Symptomatic Treatment
19%
Tumor Cell
22%
Uterine Cancer
45%
Visceral Fat
9%
Wound Complication
35%